TikoMed’s drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action
Viken, Sweden – 7[th] September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company’s lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles. In the study, ILB® potently inhibited infection by all the strains of Dengue, Zika and Yellow Fever virus in a concentration-dependent manner with IC50 for ILB® ranging from 31 to 343 μg/ml.